Shionogi & Co (TYO:4507) revised its dividend forecast for the fiscal year ending March 31, 2025, increasing the year-end dividend to 33 yen per share, up from the previous forecast of 29 yen, according to a Thursday filing on the Tokyo Stock Exchange.
The company now expects annual dividends of 184 yen per share, an increase of 24 yen from the prior year, reflecting 13 consecutive years of dividend growth.
Shionogi's strong performance, driven by the success of its treatments such as Xocova for COVID-19 and Xofluza for influenza, as well as the global expansion of its Cefiderocol sales, contributed to the revision.
The company is also advancing its growth phase, particularly with its COVID-19 treatment Ensitrelvir and HIV treatments through its ViiV Healthcare partnership.
Price (JPY): $2385.00, Change: $-35, Percent Change: -1.43%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。